Sign up
Pharma Capital

NetScientific to focus on extending lifespan as CEO reiterates confidence in portfolio firms

CEO Ian Postlethwaite said the healthcare commercialisation firm had taken measures to reduce its central function costs and was expected to have sufficient cash to operate until the end of 2020
Scientist
The firm ended 2018 with a cash balance of £2.9mln, which had increased to £3mln as of 30 April

NetScientific PLC (LON:NSCI) chief executive Ian Postlethwaite has reiterated the group’s confidence in its remaining portfolio companies, adding that the company would use its cash reserves to focus on extending its lifespan.

The CEO of the healthcare commercialisation firm said in its full-year results that after selling its interests in the Vortex Biosciences and Wanda companies for £150,000 in March, the company had taken measures to reduce its central function costs and was expected to have sufficient cash to operate until the end of 2020.

READ: Netscientific surges as peer-reviewed article confirms potential of PDS Biotech’s Versamune immunotherapy platform

Two of the company’s portfolio firms, Glycotest and PDS Biotechnology, did not require further funding, while the final firm, ProAxsis, required only a small injection of £100,000 to meet operational requirements which would be repayable in 2019.

For the year ended 31 December 2018, NetScientific reported a loss from continuing operations of £4mln, less than the £4.2mln loss the year before, while revenues rose to £245,000 from £171,000.

The firm also ended the year with a cash balance of £2.9mln, which had increased to £3mln as of 30 April.

In early trading on Wednesday, the shares were down 5.4% at 8.8p.

View full NSCI profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.